ClinicalTrials.gg
CompletedNCT01724346Updated Sep 19, 2024Results posted

Open-label Extension Study in Patients 65 Years or Older With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

A Phase 3 interventional study of Ibrutinib and Next-line ibrutinib in Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma, sponsored by Pharmacyclics LLC.. Completed at 88 sites in 16 countries. Open to participants aged 65 Years and older. Per ClinicalTrials.gov, last updated 2024-09-19.

Sponsored by Pharmacyclics LLC. (part of AbbVie) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
269
Allocation
Non-randomized
Ages
65 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 83 studies testing ibrutinib in Leukemia, Lymphocytic, Chronic, B-Cell — 8 open to participants now, 28 under way, 4 of them phase 3. ibrutinib · Leukemia, Lymphocytic, Chronic, B-Cell.

Enrollment
10th of 83
269 · median 44
Started
2013
with 6 others
Phase 3
14 of 83
none open now
Registered
12th of 83
by date
Lead sponsor
10 of 83
Pharmacyclics LLC.

Among the 83 studies testing ibrutinib in Leukemia, Lymphocytic, Chronic, B-Cell, this one is the 10th largest by enrollment, is one of 7 that started in 2013, is one of 14 in phase 3, and was the 12th registered.

Leukemia, Lymphocytic, Chronic, B-Cell

2,036 studies on the registry are indexed under Leukemia, Lymphocytic, Chronic, B-Cell; 236 are open to participants now.

Browse Leukemia, Lymphocytic, Chronic, B-Cell studies →

Open to participants now

8 of the 83 studies testing ibrutinib in Leukemia, Lymphocytic, Chronic, B-Cell are open now, in 12 countries. Recruiting first, the newest first:

3 more — sign in →

By country, each count listing its studies:

All 8 open studies →

About ibrutinib

ibrutinib: first FDA approval 2013 (IMBRUVICA), first EMA approval 2014. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 187 Leukemia, Lymphocytic, Chronic, B-Cell studies recruiting now, 150 (80%) set no upper age limit and 15 (8%) stop at 75 or younger; 17 take children under 18; 12 take healthy volunteers.

This study: 65 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 83 studies testing ibrutinib in Leukemia, Lymphocytic, Chronic, B-Cell, or all of them as a file.
02

Study summary

An Open-label Extension Study in Patients 65 Years or Older with Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL) Who Participated in Study PCYC-1115-CA (Ibrutinib versus Chlorambucil)

03

Conditions studied

  • Chronic Lymphocytic Leukemia
  • Small Lymphocytic Lymphoma

Keywords

  • CLL
  • SLL
04

Who can participate

Ages eligible
65 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Randomized in the parent study, PCYC-1115-CA
  2. for Study PCYC-1116-CA
  3. Independent review committee (IRC)-confirmed disease progression (PD) in the parent study PCYC-1115-CA or closure of the parent study

Exclusion criteria

Exclusion Criteria:

  1. Disease progression involving the central nervous system (CNS) or transformation to another histology
  2. Intervening chemotherapy, immunotherapy, or agent specifically to treat CLL if administered before date of IRC confirmed progressive disease
  3. In the 4 weeks before dosing: radiation therapy, major surgery, or receipt of an investigational drug
  4. Requirement for treatment with a strong inhibitor
  5. Uncontrolled systemic infection or requirement for IV antibiotics
  6. Noncompliance on the parent study(PCYC-1115-CA)
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
269 participants (actual)

Study arms

  • Experimental
    Chlorambucil

    Participants who received chlorambucil 0.5 mg/kg (to maximum 0.8 mg/kg) Days 1 and 15 of 28-day cycle up to 12 cycles in Study 1115. In Study 1116, participants had the option to crossover to next-line ibrutinib 420 mg/day after disease progression (PD).

    Drug: Ibrutinib

  • Experimental
    Ibrutinib

    Participants who received ibrutinib 420 mg daily in Study 1115 received ibrutinib orally once daily. Participants continuing in first-line ibrutinib therapy entered Study 1116 at the ibrutinib dose tolerated in Study 1115.

    Drug: Next-line ibrutinib

Interventions

  • Ibrutinib 420 mg (3 x 140-mg capsules) is administered orally once daily

    Also known as: PCI-32765

  • Ibrutinib 420 mg (3 x 140-mg capsules) is administered orally once daily

    Also known as: PCI-32765

06

What researchers measure

Primary outcomes

  1. Progression Free Survival (PFS) Based on Investigator Assessment

    PFS is defined as the time from the date of randomization to the date of disease progression determined by the investigator or date of death from any cause, whichever occurs first, regardless of the use of subsequent antineoplastic therapy prior to disease progression (PD) or death. Estimated by Kaplan-Meier method.

    Time frame: Median overall follow-up of 82.7 months

Secondary outcomes

  1. Progression Free Survival After Initiation of Subsequent Anticancer Therapy (PFS2)

    PFS2 is defined as the time from the date of randomization to the earliest occurrence of the following three types of events: * PD per investigator response assessment after initiation of the first subsequent anti-cancer therapy * Initiation of second subsequent anti-cancer therapy * Death due to any cause, regardless of administration of subsequent anticancer therapy. Kaplan-Meier landmark estimate of the PFS2 rate at 60 months (that is, the estimated percentage of participants with PFS2 at Month 60) is presented.

    Time frame: Median overall follow-up of 82.7 months

  2. Overall Survival (OS)

    OS is defined as the time from randomization to death due to any cause. Kaplan-Meier landmark estimate of the OS rate at 60 months (that is, the estimated percentage of participants with OS at Month 60) is presented.

    Time frame: Median overall follow-up of 82.7 months

  3. Time to Next Treatment (TTNT)

    Time from randomization to initiation of any subsequent treatment for chronic lymphocytic leukemia (CLL).

    Time frame: Median overall follow-up of 82.7 months

  4. Overall Response Rate (ORR)

    ORR is defined as the percentage of participants who achieve complete response (CR), complete response with an incomplete marrow recovery (CRi), nodular partial response (nPR), or partial response (PR), as determined by the investigator at or prior to initiation of subsequent antineoplastic therapy according to the International Workshop on CLL (iwCLL) 2008 criteria with the 2012 iwCLL modification stating that treatment-related lymphocytosis in the setting of improvement in other parameters was not considered as PD and the 2013 iwCLL clarification of criteria for a partial response to therapy.

    Time frame: Median overall follow-up of 82.7 months

  5. Rate of Minimal Residual Disease (MRD) Negativity

    Percentage of participants who achieved MRD-negative response defined as \< 1 CLL cell per 10,000 leukocytes as assessed by flow cytometry of a bone marrow aspirate and/or peripheral blood sample per central laboratory at or prior to initiation of subsequent antineoplastic therapy.

    Time frame: Median overall follow-up of 82.7 months

  6. Duration of Response (DOR)

    DOR will be calculated for the participants achieving a protocol-defined response (Halleck 2008; CR, CRi, nPR, PR) per investigator assessment and is defined as time from the date of initial response including PR with lymphocytosis to the date of disease progression or the date of death from any cause, whichever occurs first.

    Time frame: Median overall follow-up of 82.7 months

07

Results

Posted Sep 19, 2024

Participant flow

This extension study provided ongoing treatment and follow-up for participants previously enrolled in the parent study (PCYC-1115-CA; Study 1115; NCT01722487). Participants entered this study upon Independent Review Committee (IRC)-confirmed progressive disease (PD) or the closure of Study 1115, whichever was earlier.

Participant flow — Overall Study
MilestoneIbrutinibChlorambucil
Started136133
Received next-line ibrutinib after pd078
Completed5763
Not completed7970
Withdrew: Death4242
Withdrew: Lost to follow-up51
Withdrew: Withdrawal by subject2719
Withdrew: Did not rollover from parent study58

Outcome measures

PrimaryProgression Free Survival (PFS) Based on Investigator Assessment

PFS is defined as the time from the date of randomization to the date of disease progression determined by the investigator or date of death from any cause, whichever occurs first, regardless of the use of subsequent antineoplastic therapy prior to disease progression (PD) or death. Estimated by Kaplan-Meier method.

Time frame:
Median overall follow-up of 82.7 months
Reported as:
Median · months
Progression Free Survival (PFS) Based on Investigator Assessment
monthsIbrutinibChlorambucil
Progression Free Survival (PFS) Based on Investigator Assessment106.9 (83.4 to NA)15.0 (10.2 to 19.4)
Statistical analysis
  • Ibrutinib vs Chlorambucil · Log Rank · p = < 0.0001 (P-value is from stratified log-rank test.) · Hazard ratio (hr): 0.155 · 95% CI 0.110 to 0.220
SecondaryProgression Free Survival After Initiation of Subsequent Anticancer Therapy (PFS2)

PFS2 is defined as the time from the date of randomization to the earliest occurrence of the following three types of events: * PD per investigator response assessment after initiation of the first subsequent anti-cancer therapy * Initiation of second subsequent anti-cancer therapy * Death due to any cause, regardless of administration of subsequent anticancer therapy. Kaplan-Meier landmark estimate of the PFS2 rate at 60 months (that is, the estimated percentage of participants with PFS2 at Month 60) is presented.

Time frame:
Median overall follow-up of 82.7 months
Reported as:
Number · percentage of participants
Progression Free Survival After Initiation of Subsequent Anticancer Therapy (PFS2)
percentage of participantsIbrutinibChlorambucil
Progression Free Survival After Initiation of Subsequent Anticancer Therapy (PFS2)79.3 (71.1 to 85.4)58.4 (48.8 to 66.7)
SecondaryOverall Survival (OS)

OS is defined as the time from randomization to death due to any cause. Kaplan-Meier landmark estimate of the OS rate at 60 months (that is, the estimated percentage of participants with OS at Month 60) is presented.

Time frame:
Median overall follow-up of 82.7 months
Reported as:
Number · percentage of participants
Overall Survival (OS)
percentage of participantsIbrutinibChlorambucil
Overall Survival (OS)82.8 (75.0 to 88.3)68.4 (59.1 to 75.9)
SecondaryTime to Next Treatment (TTNT)

Time from randomization to initiation of any subsequent treatment for chronic lymphocytic leukemia (CLL).

Time frame:
Median overall follow-up of 82.7 months
Reported as:
Median · months
Time to Next Treatment (TTNT)
monthsIbrutinibChlorambucil
Time to Next Treatment (TTNT)NA (NA to NA)25.1 (21.8 to 27.9)
Statistical analysis
  • Ibrutinib vs Chlorambucil · Log Rank · p = < 0.0001 (P value is from stratified log-rank test.) · Hazard ratio (hr): 0.087 · 95% CI 0.054 to 0.141
SecondaryOverall Response Rate (ORR)

ORR is defined as the percentage of participants who achieve complete response (CR), complete response with an incomplete marrow recovery (CRi), nodular partial response (nPR), or partial response (PR), as determined by the investigator at or prior to initiation of subsequent antineoplastic therapy according to the International Workshop on CLL (iwCLL) 2008 criteria with the 2012 iwCLL modification stating that treatment-related lymphocytosis in the setting of improvement in other parameters was not considered as PD and the 2013 iwCLL clarification of criteria for a partial response to therapy.

Time frame:
Median overall follow-up of 82.7 months
Reported as:
Number · percentage of participants
Overall Response Rate (ORR)
percentage of participantsIbrutinibChlorambucil
Overall Response Rate (ORR)91.236.8
Statistical analysis
  • Ibrutinib vs Chlorambucil · Cochran-Mantel-Haenszel · p = < 0.0001 (Rate ratio and p-value are based on Cochran-Mantel-Haenszel chi-square test stratified by Eastern Cooperative Oncology Group (ECOG; 0-1 vs 2) and Rai stage (0/I/II vs III/IV) at baseline.) · Rate ratio: 2.496 · 95% CI 1.990 to 3.131
SecondaryRate of Minimal Residual Disease (MRD) Negativity

Percentage of participants who achieved MRD-negative response defined as \< 1 CLL cell per 10,000 leukocytes as assessed by flow cytometry of a bone marrow aspirate and/or peripheral blood sample per central laboratory at or prior to initiation of subsequent antineoplastic therapy.

Time frame:
Median overall follow-up of 82.7 months
Reported as:
Number · percentage of participants
Rate of Minimal Residual Disease (MRD) Negativity
percentage of participantsIbrutinibChlorambucil
Rate of Minimal Residual Disease (MRD) Negativity5.10
SecondaryDuration of Response (DOR)

DOR will be calculated for the participants achieving a protocol-defined response (Halleck 2008; CR, CRi, nPR, PR) per investigator assessment and is defined as time from the date of initial response including PR with lymphocytosis to the date of disease progression or the date of death from any cause, whichever occurs first.

Time frame:
Median overall follow-up of 82.7 months
Reported as:
Median · months
Duration of Response (DOR)
monthsIbrutinibChlorambucil
Duration of Response (DOR)NA (84.0 to NA)29.7 (15.2 to 40.4)

Adverse events

Collected over All-cause mortality: median overall follow-up of 82.7 months. Adverse events: from first dose of any study treatment to 30 days after last dose of study treatment or initiation of subsequent therapy whichever was earlier. Median treatment duration was: 74.0 months for Ibrutinib arm; 7.1 months for Chlorambucil arm; 26.9 months for Crossover Next-line Ibrutinib arm.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Ibrutinib42/135 (31.1%)111/135 (82.2%)134/135 (99.3%)
Chlorambucil44/132 (33.3%)33/132 (25%)120/132 (90.9%)
Next-line Ibrutinib After PD on Chlorambucil24/78 (30.8%)49/78 (62.8%)75/78 (96.2%)
Most frequent serious events
Showing 10 of 299
Most frequent serious events
EventIbrutinibChlorambucilNext-line Ibrutinib After PD on Chlorambucil
PNEUMONIAInfections and infestations27/1352/1327/78
ATRIAL FIBRILLATIONCardiac disorders11/1351/1326/78
BASAL CELL CARCINOMANeoplasms benign, malignant and unspecified (incl cysts and polyps)9/1350/1321/78
URINARY TRACT INFECTIONInfections and infestations6/1350/1325/78
ABDOMINAL PAINGastrointestinal disorders1/1350/1323/78
PYREXIAGeneral disorders4/1355/1321/78
CARDIAC FAILURECardiac disorders5/1350/1321/78
SEPSISInfections and infestations5/1350/1320/78
HYPONATRAEMIAMetabolism and nutrition disorders5/1350/1320/78
SYNCOPENervous system disorders5/1352/1321/78
Most frequent other events
Showing 10 of 117
Most frequent other events
EventIbrutinibChlorambucilNext-line Ibrutinib After PD on Chlorambucil
DIARRHOEAGastrointestinal disorders67/13522/13227/78
FATIGUEGeneral disorders55/13551/13218/78
NAUSEAGastrointestinal disorders43/13552/13213/78
COUGHRespiratory, thoracic and mediastinal disorders52/13520/13219/78
ARTHRALGIAMusculoskeletal and connective tissue disorders41/13510/13222/78
OEDEMA PERIPHERALGeneral disorders39/13511/13215/78
UPPER RESPIRATORY TRACT INFECTIONInfections and infestations38/13523/13220/78
HYPERTENSIONVascular disorders37/1350/13210/78
PYREXIAGeneral disorders36/13514/1329/78
WEIGHT DECREASEDInvestigations34/13516/13212/78

Baseline characteristics

Age, Continuous
Age, Continuous(years)IbrutinibChlorambucilTotal
Mean73.1 ± 5.6773.4 ± 5.9573.3 ± 5.81
Sex: Female, Male
Sex: Female, Male(Participants)IbrutinibChlorambucilTotal
Female4852100
Male8881169
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)IbrutinibChlorambucilTotal
Hispanic or Latino325
Not Hispanic or Latino132129261
Unknown or Not Reported123
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)IbrutinibChlorambucilTotal
White120125245
Asian9413
Black or African American538
Native Hawaiian or Other Pacific Islander011
Subject declined to answer/unknown202
08

Study locations

88 sites
  • City of Hope /ID# 1116-0047
    Duarte, California 91010, United States
  • Moores Cancer Center at UC San Diego /ID# 1116-0408
    La Jolla, California 92093, United States
  • Stanford University/Stanford Cancer Center, Campus Drive /ID# 1116-0038
    Stanford, California 94305, United States
  • University of Chicago /ID# 1116-0126
    Chicago, Illinois 60637, United States
  • Norton Cancer Institute - St Matthews /ID# 1116-0071
    Louisville, Kentucky 40207, United States
  • Comprehensive Cancer Centers of Nevada /ID# 1116-0712
    Henderson, Louisiana 89052, United States
  • University of Massachusetts - Worcester /ID# 1116-0307
    Worcester, Massachusetts 01655, United States
  • Washington University-School of Medicine /ID# 1116-0221
    Saint Louis, Missouri 63110, United States
  • Northwell Health/Long Island Jewish Hospital /ID# 1116-0350
    New Hyde Park, New York 11042, United States
  • University of Rochester Medical Center /ID# 1116-0127
    Rochester, New York 14642-0001, United States
  • Southeastern Medical Oncology Center /ID# 1116-0656
    Goldsboro, North Carolina 27534, United States
  • Kaiser Permanente - Northwest /ID# 1116-0677
    Portland, Oregon 97227, United States
  • University of Pittsburgh - UPMC (Hillman Cancer Center) /ID# 1116-0050
    Pittsburgh, Pennsylvania 15232, United States
  • University of Texas MD Anderson Cancer Center /ID# 1116-0032
    Houston, Texas 77030, United States
  • Oncology of San Antonio /ID# 1116-0653
    San Antonio, Texas 78240, United States
  • Providence St. Mary Regional Cancer Center /ID# 1116-0731
    Walla Walla, Washington 99362, United States
  • St George Hospital /ID# 1116-0654
    Kogarah, New South Wales 2217, Australia
  • Princess Alexandra Hospital /ID# 1116-0503
    Woolloongabba, Queensland 4102, Australia
  • Flinders Medical Centre /ID# 1116-0163
    Bedford, Park, South Australia 5042, Australia
  • Royal Hobart /ID# 1116-0555
    Hobart, Tasmania 7000, Australia
  • Box Hill Hospital /ID# 1116-0193
    Box Hill, Victoria 3128, Australia
  • Monash Medical Centre /ID# 1116-0556
    Clayton, Victoria 3168, Australia
  • St Vincent's Hospital Melbourne /ID# 1116-0501
    Fitzroy Melbourne, Victoria 3065, Australia
  • Austin Health /ID# 1116-0170
    Heidelberg, Victoria 3084, Australia
  • ZNA Cadix /ID# 1116-0561
    Antwerp, Antwerpen 2030, Belgium
  • UCL Saint-Luc /ID# 1116-0164
    Woluwe-Saint-Lambert, Bruxelles-Capitale 1200, Belgium
  • UZ Gent /ID# 1116-0560
    Gent, Oost-Vlaanderen 9000, Belgium
  • Universitair Ziekenhuis Leuven /ID# 1116-0559
    Leuven, Vlaams-Brabant 3000, Belgium
  • Tom Baker Cancer Centre /ID# 1116-0157
    Calgary, Alberta T2N 4N2, Canada
  • Cross Cancer Institute /ID# 1116-0018
    Edmonton, Alberta T6G 1Z2, Canada
  • Beijing Cancer Hospital /ID# 1116-0670
    Beijing, Beijing 100142, China
  • Peking University Third Hospital /ID# 1116-0673
    Beijing, Beijing 100191, China
  • Jiangsu Province Hospital /ID# 1116-0671
    Nanjing, Jiangsu 210029, China
  • The First Affiliated Hospital, Zhejiang University School of Medicine /ID# 1116-0675
    Hangzhou, Zhejiang 310003, China
  • Fakultni nemocnice Brno /ID# 1116-0562
    Brno, 613 00, Czechia
  • Fakultni nemocnice Hradec Kralove /ID# 1116-0564
    Hradec Kralove, 500 05, Czechia
  • Fakultni nemocnice Plzen /ID# 1116-0566
    Plzen, 305 99, Czechia
  • St James Hospital /ID# 1116-0570
    Dublin 8, Dublin D08 NHY1, Ireland
  • University Hospital Galway /ID# 1116-0571
    Galway, H91 YR71, Ireland
  • Rambam Health Care Campus /ID# 1116-0576
    Haifa, H_efa 3109601, Israel
  • Bnai Zion Medical Center /ID# 1116-0573
    Haifa, H_efa 3339419, Israel
  • Rabin Medical Center /ID# 1116-0575
    Haifa, H_efa 4941492, Israel
  • Galilee Medical Center /ID# 1116-0578
    Nahariya, HaTsafon 2210001, Israel
  • Shaare Zedek Medical Center /ID# 1116-0577
    Jerusalem, Yerushalayim 91031, Israel
  • Tel Aviv Sourasky Medical Center /ID# 1116-0856
    Tel Aviv-Yafo, 6423906, Israel
  • Institute of Hematology Seràgnoli /ID# 1116-0580
    Bologna, Emilia-Romagna 40138, Italy
  • Ospedale San Raffaele IRCCS /ID# 1116-0523
    Milan, Milano 20132, Italy
  • ASST Grande Ospedale Metropolitano Niguarda /ID# 1116-0581
    Milan, Milano 20162, Italy
  • Università La Sapienza /ID# 1116-0583
    Rome, Roma 00161, Italy
  • Fondazione IRCCS Ca Granda Ospedale Maggiore Policlinico /ID# 1116-0584
    Milan, 20122, Italy
  • Azienda Ospedaliero-Universitaria di Modena /ID# 1116-0524
    Modena, 41124, Italy
  • Azienda Ospedaliero Universitaria Maggiore della Carita di Novara /ID# 1116-0582
    Novara, 28100, Italy
  • Universita degli Studi di Padova /ID# 1116-0527
    Padova, 35128, Italy
  • Policlinico Universitario A Gemelli /ID# 1116-0891
    Rome, 00168, Italy
  • Auckland City Hospital /ID# 1116-0588
    Grafton, Auckland 1023, New Zealand
  • North Shore Hospital /ID# 1116-0663
    Takapuna, Auckland 0622, New Zealand
  • Haematology Waikato Hospital /ID# 1116-0586
    Hamilton, Waikato 3204, New Zealand
  • Wellington Blood and Cancer Centre /ID# 1116-0587
    Wellington South, Wellington 6021, New Zealand
  • Canterbury Health Labs Canterbury Disrict Health Board /ID# 1116-0589
    Christchurch, 8011, New Zealand
  • MTZ Clinical Research Sp. z o.o. /ID# 1116-0363
    Warszawa, Mazowieckie 02-172, Poland
  • Szpital Specjalistyczny w Brzozowie Podkarpacki Osrodek Onkologiczny im. ks. B. /ID# 1116-0592
    Brzozow, Podkarpackie 36-200, Poland
  • Samodzielny Publiczny Szpital Klinczny Nr-1- Akademickie Cenrum Klinic /ID# 1116-0529
    Gdańsk, Pomorskie 80-952, Poland
  • Samodzielny Publiczny Zaklad Opieki Zdrowotnej /ID# 1116-0591
    Chorzow, Slaskie 41-500, Poland
  • Medical Univ. of Lodz and Copernicus Memorial Hospital /ID# 1116-0531
    Lodz, 93-510, Poland
  • State Institution of Health of the Ryazan Regional Clinical Hospital /ID# 1116-0707
    Ryazan, Ryazanskaya Oblast 390039, Russian Federation
  • Hospital Duran i Reynals /ID# 1116-0604
    Hospitalet de Llobregat, Barcelona 08907, Spain
  • Hospital Universitario Puerta de Hierro - Majadahonda /ID# 1116-0536
    Majadahonda, Madrid 28222, Spain
  • Hospital Universitario Vall d'Hebron /ID# 1116-0534
    Barcelona, 08035, Spain
  • Hospital Clinic de Barcelona /ID# 1116-0533
    Barcelona, 08036, Spain
  • Hospital Santa Creu i Sant Pau /ID# 1116-0535
    Barcelona, 08041, Spain
  • Hospital Universitario HM Sanchinarro /ID# 1116-0537
    Madrid, 28050, Spain
  • Gazi Universitesi Tip Fakultes /ID# 1116-0608
    Yenimahalle, Ankara 06560, Turkey
  • Ankara Universitesi Tip Fakultesi Ibn-i Sina /ID# 1116-0606
    Ankara, 06590, Turkey
  • Ic Hastaliklari Anabilim Dali/Ege University Medical Faculty /ID# 1116-0714
    Izmir, 35040, Turkey
  • Dokuz Eylul University Medical Faculty /ID# 1116-0601
    Izmir, 35340, Turkey
  • Erciyes Universiitesi Tip Fakultesi /ID# 1116-0602
    Kayseri, 38039, Turkey
  • CNE Vinnytsya Regional Clinical Hospital named after N.I.Pirogov /ID# 1116-0595
    Vinnytsia, Vinnytska Oblast 21018, Ukraine
  • Communal Nonprofit Enterprise Cherkasy Regional Oncology Dispensary /ID# 1116-0597
    Cherkasy, 18009, Ukraine
  • Municipal Non-Profit Enterprise City Clinical Hospital 4 of Dnipro City Council /ID# 1116-0594
    Dnipro, 49102, Ukraine
  • SI Institute of Blood Pathology and Transfusion Medicine of NAMS of Ukraine /ID# 1116-0596
    Lviv, 79044, Ukraine
  • University Hospitals Dorset NHS Foundation Trust /ID# 1116-0551
    Poole, Dorset BH15 2JB, United Kingdom
  • University Hospital Southampton NHS Foundation Trust /ID# 1116-0367
    Southampton, Hampshire SO16 6YD, United Kingdom
  • Nottingham University Hospitals NHS Trust /ID# 1116-0548
    Nottingham, Nottinghamshire NG5 1PB, United Kingdom
  • Oxford University Hospitals NHS Foundation Trust /ID# 1116-0668
    Oxford, Oxfordshire OX3 9DU, United Kingdom
  • Cardiff & Vale University Health Board /ID# 1116-0607
    Cardiff, Wales CF14 4XN, United Kingdom
  • East Suffolk and North Essex NHS Foundation Trust /ID# 1116-0549
    Colchester, CO4 5JL, United Kingdom
  • Leeds Teaching Hospitals NHS Trust /ID# 1116-0550
    Leeds, LS9 7TF, United Kingdom
  • King's College Hospital NHS Foundation Trust /ID# 1116-0544
    London, SE5 9RS, United Kingdom
09

References and documents

Publications

  • Barr PM, Owen C, Robak T, Tedeschi A, Bairey O, Burger JA, Hillmen P, Coutre SE, Dearden C, Grosicki S, McCarthy H, Li JY, Offner F, Moreno C, Zhou C, Hsu E, Szoke A, Kipps TJ, Ghia P. Up to 8-year follow-up from RESONATE-2: first-line ibrutinib treatment for patients with chronic lymphocytic leukemia. Blood Adv. 2022 Jun 14;6(11):3440-3450. doi: 10.1182/bloodadvances.2021006434. PubMed 35377947 ↗
  • Coutre SE, Byrd JC, Hillmen P, Barrientos JC, Barr PM, Devereux S, Robak T, Kipps TJ, Schuh A, Moreno C, Furman RR, Burger JA, O'Dwyer M, Ghia P, Valentino R, Chang S, Dean JP, James DF, O'Brien SM. Long-term safety of single-agent ibrutinib in patients with chronic lymphocytic leukemia in 3 pivotal studies. Blood Adv. 2019 Jun 25;3(12):1799-1807. doi: 10.1182/bloodadvances.2018028761. PubMed 31196847 ↗
  • Barr PM, Robak T, Owen C, Tedeschi A, Bairey O, Bartlett NL, Burger JA, Hillmen P, Coutre S, Devereux S, Grosicki S, McCarthy H, Li J, Simpson D, Offner F, Moreno C, Zhou C, Styles L, James D, Kipps TJ, Ghia P. Sustained efficacy and detailed clinical follow-up of first-line ibrutinib treatment in older patients with chronic lymphocytic leukemia: extended phase 3 results from RESONATE-2. Haematologica. 2018 Sep;103(9):1502-1510. doi: 10.3324/haematol.2018.192328. Epub 2018 Jun 7. PubMed 29880603 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Requests for access to individual participant data from clinical studies conducted by Pharmacyclics LLC, an AbbVie Company, can be submitted through Yale Open Data Access (YODA) Project site at the following link.

Data sharing details ↗ · yoda.yale.edu

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Dec 2013 to primary completion in Aug 2023, 116 months.

Results were first posted in Sep 2024, 1 year 1 month after primary completion.

Of 57 industry-sponsored phase 3 interventional studies under Leukemia, Lymphocytic, Chronic, B-Cell, half reached primary completion within 53 months of starting (the median), counting those still running; a quarter within 41 and three quarters within 73. This study's 116 months is above that.

Counting every sponsor, half of 83 studies reached it within 59 months; a quarter within 43 and three quarters within 76.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 2, 2012
First posted
Nov 9, 2012
StartActual
Dec 3, 2013
Primary completionActual
Aug 18, 2023
CompletionActual
Aug 18, 2023
Results first posted
Sep 19, 2024
Last update
Sep 19, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 19, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01724346
Lead sponsor
Pharmacyclics LLC.
Responsible party
Sponsor
First posted
Nov 9, 2012
Start date
Dec 3, 2013
Primary completion
Aug 18, 2023
Completion
Aug 18, 2023
Results posted
Sep 19, 2024
Last update
Sep 19, 2024

Study contacts

ABBVIE INC.
study director · AbbVie

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ibrutinib

Start the discussion